title: Expression of the FOS proto-oncogene protein in brain after ICV administration of Tyr-W-MIF-1 (Tyr-Pro-Trp-Gly-NH2).
abstract: Tyr-W-MIF-1 is a tetrapeptide recently isolated from brain that has opiate modulating activity. In this study, we used immunocytochemical (ICC) detection of FOS proto-oncogene protein to map brain areas activated by an ICV injection of Tyr-W-MIF-1 (200 micrograms). The analgesic effect of the peptide, which lasted 1 h, was confirmed in each rat with the tail flick test. FOS was activated in several limbic structures, including the cingulate and infralimbic cortex, nucleus accumbens, and central nucleus of the amygdala. FOS activation also occurred in several diencephalic nuclei, including the supraoptic, paraventricular, and periventricular nuclei of the hypothalamus, and the paraventricular nucleus of the thalamus. Several activated areas contained mu-opiate receptors. However, despite the known selectivity of Tyr-W-MIF-1 for mu receptors, FOS immunoreactivity was also induced in nuclei of the amygdala, hypothalamus, and thalamus, where concentrations of kappa receptors were high but those of mu and delta receptors were not detected. The results show that Tyr-W-MIF-1 induces FOS activation in several brain areas, including but not limited to, areas associated with nociception and stress-induced analgesia.
authors.affiliation: VA Medical Center, New Orleans, LA 70146.
authors.forename: K A
authors.initials: KA
authors.lastname: Gergen
authors.forename: S L
authors.initials: SL
authors.lastname: Chang
authors.forename: Y F
authors.initials: YF
authors.lastname: Niu
authors.forename: A J
authors.initials: AJ
authors.lastname: Kastin
authors.forename: J E
authors.initials: JE
authors.lastname: Zadina
mesh_terms: D000698:Analgesia; D000818:Animals; D001921:Brain / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D002552:Cerebral Ventricles / Q000187:drug effects / Q000502:physiology*; D015870:Gene Expression; D007150:Immunohistochemistry; D007276:Injections, Intraventricular; D009075:MSH Release-Inhibiting Hormone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D008297:Male; D009292:Narcotic Antagonists / Q000494:pharmacology*; D009928:Organ Specificity; D016760:Proto-Oncogene Proteins c-fos / Q000096:biosynthesis*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012016:Reference Values
chemical_list: D009292:Narcotic Antagonists; D016760:Proto-Oncogene Proteins c-fos; C077532:tyrosyl-prolyl-tryptophyl-glycinamide; D009075:MSH Release-Inhibiting Hormone